| abstract |
Provided are a B7H4-targeting antibody or a variant thereof, and a bispecific antibody containing the B7H4-targeting antibody, wherein the B7H4-targeting antibody comprises a light chain variable region and a heavy chain variable region. The variant has an amino acid mutation in the light chain variable region or heavy chain variable region of the antibody and can maintain the function of the antibody. The B7H4-targeting antibody has the activity of binding to human B7H4 and cynomolgus macaque B7H4, and does not cross-react with other B7 family members. The B7H4-targeting antibody exhibits good anti-tumor activity, T-cell activation activity and internalization activity in in-vivo and in-vitro experiments, and is more suitable for use as an ADC drug. Further provided is a bispecific antibody targeting B7H4 and CD3, which has a longer half-life, retains good stability and hydrophilicity, and reduces toxicity while ensuring efficacy. |